ArticleSurgical endoscopy2026
One PPI may not fit all-prevalence of CYP2C19 phenotypes in patients with Barrett's esophagus.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBarrett's esophagus (BE) is associated with longstanding gastroesophageal reflux disease and can progress to esophageal adenocarcinoma. BE is primarily managed with proton pump inhibitors (PPIs), which are metabolized by cytochrome P450 2C19 (CYP2C19). CYP2C19 polymorphisms affect PPI plasma levels, which are categorized as poor (PM), intermediate (IM), normal (NM), rapid (RM), and ultra-rapid (UM) metabolizers. This study assessed the prevalence of CYP2C19 phenotypes in patients with BE and concomitant hiatal hernias (HH).
methodsThis was a single-institution retrospective review of medically-managed adult BE patients with CYP2C19 genotyping. Patients were grouped by HH size (small, medium, or large). CYP2C19 phenotypes were stratified by genotype as: PM/IM, NM, and RM/UM based on anticipated need for PPI dose adjustment. Descriptive statistics and a multivariable analysis to determine factors associated with RM/UM were used.
resultsA total of 97 patients (58% female, median age 61, mean BMI 27.5) were included, and CYP2C19 phenotypes were PM/IM (32%, 95% CI 0.27-0.41), NM (37%, 95% CI 0.27-0.47), and RM/UM (31%, 95% CI 0.22-0.40). HHs were present in 59 patients. Notably, 17% of RM/UM patients had concomitant severe erosive esophagitis, LA grade C/D. On sub-analysis, there was a trend toward higher prevalence of RM/UMs(53%) compared with PM/IM/NM (33%, p = 0.06) in patients who did not have a HH. The presence of HHs tended to be more frequent in the PM/IM/NMs (67%) compared with RM/UMs (47%, p = 0.06). On multivariable analysis, this trend persisted with HHs being less present with RM/UMs (OR 0.43, 95% CI 0.18-1.03).
conclusionThere is a trend toward high prevalence of the RM/UM phenotype in patients with BE. Patients with RM/UM phenotype could benefit from PPI dose optimization. Given the poor survival associated with esophageal adenocarcinoma and its association with BE, assessing CYP2C19 phenotype to optimize PPI dosage and effectiveness could have significant public health implications, and additional prospective studies are needed.
Indexed as
Identifiers
42533164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.